BioXcel Therapeutics (BTAI) Projected to Post Earnings on Thursday

BioXcel Therapeutics (NASDAQ:BTAI) is projected to release its Q4 2025 results before the market opens on Thursday, March 26th. Analysts expect BioXcel Therapeutics to post earnings of ($0.58) per share and revenue of $0.1520 million for the quarter. Interested persons can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Friday, April 3, 2026 at 9:30 AM ET.

BioXcel Therapeutics Trading Down 2.7%

Shares of BTAI opened at $1.43 on Wednesday. The company has a market cap of $31.27 million, a price-to-earnings ratio of -0.15 and a beta of 0.18. BioXcel Therapeutics has a 1-year low of $1.17 and a 1-year high of $8.08. The company’s fifty day simple moving average is $1.64 and its 200 day simple moving average is $2.01.

Hedge Funds Weigh In On BioXcel Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. Diversify Wealth Management LLC bought a new position in shares of BioXcel Therapeutics during the second quarter worth approximately $27,000. HRT Financial LP bought a new stake in BioXcel Therapeutics in the 4th quarter valued at $28,000. XTX Topco Ltd acquired a new position in BioXcel Therapeutics in the 2nd quarter valued at $42,000. Goldman Sachs Group Inc. acquired a new position in BioXcel Therapeutics in the 1st quarter valued at $50,000. Finally, Geode Capital Management LLC increased its position in BioXcel Therapeutics by 27.7% during the 2nd quarter. Geode Capital Management LLC now owns 28,182 shares of the company’s stock worth $51,000 after buying an additional 6,120 shares during the period. Institutional investors and hedge funds own 30.68% of the company’s stock.

Analyst Ratings Changes

BTAI has been the subject of a number of analyst reports. HC Wainwright decreased their price objective on shares of BioXcel Therapeutics from $10.00 to $6.00 and set a “buy” rating for the company in a research report on Thursday, March 5th. Rodman & Renshaw initiated coverage on shares of BioXcel Therapeutics in a report on Tuesday, March 17th. They issued a “buy” rating and a $17.00 target price on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of BioXcel Therapeutics in a report on Wednesday, January 21st. Finally, Zacks Research upgraded shares of BioXcel Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, March 9th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, BioXcel Therapeutics currently has an average rating of “Hold” and an average target price of $11.50.

About BioXcel Therapeutics

BioXcel Therapeutics, Inc is a biopharmaceutical company leveraging an AI-driven drug development platform to identify and advance novel or repurposed therapies in neuroscience and immunology. The proprietary BioXcel AI engine analyzes preclinical and clinical data to reveal new therapeutic applications for existing small molecules and biologics, aiming to streamline development timelines and improve patient outcomes.

BioXcel’s commercial portfolio includes two FDA-approved therapies. IGALMI® (dexmedetomidine) is indicated for the acute treatment of agitation in schizophrenia or bipolar I disorder, offering a noninvasive, sublingual delivery option.